AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
New first-in-human study initiations feature yet more in vivo Car assets.
Intismeran autogene’s Interpath-001 trial reads out this year.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
